Sign up
Pharma Capital

ImmuPharma says pre-clinical study points to other indications for lead drug

Currently being developed to treat lupus, peptide P140 may hold the potential to treat another painful autoimmune disease
vials be processed
The findings were encouraging for a drug that's already known to be safe and well tolerated

Pre-clinical work by ImmuPharma PLC (LON:IMM) on P140, the peptide currently being developed as Lupuzor for the treatment of people with lupus, reveals it may have other potential indications.  

The company's co-founder, Professor Sylviane Muller, and her team believe the drug could be deployed to treat an autoimmune disease called chronic inflammatory demyelinating polyneuropathy, or CIDP.

This a condition where medication is currently lacking and which is characterised by fatigue, diminished or absent tendon reflexes and sensory deficits, usually starting in the hands and feet.

CLICK HERE: For the full announcement 

The results of the pre-clinical study have been published in the Journal of Autoimmunity.

"Over the last couple of years we have provided further evidence of the role the P140 peptide can take in the potential treatment of other autoimmune diseases in addition to Lupus," said Muller.

"We are delighted that these results demonstrate positive pre-clinical data in a murine model of CIDP, which has no available disease-specific treatment.  We look forward to providing a further update on the progress of our CIDP programme in due course."

 

Ian_55ae0ddd437b7.jpg
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future IMM Company articles
View full IMM profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.